Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bortezomib”

928 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 928 results

Large-scale testing (Phase 3)Study completedNCT01788020
What this trial is testing

Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia

Who this might be right for
Waldenström's Macroglobulinemia
University of Ulm 202
Testing effectiveness (Phase 2)Study completedNCT00511069
What this trial is testing

Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia

Who this might be right for
Leukemia
University of Bologna 3
Large-scale testing (Phase 3)Study completedNCT00546780
What this trial is testing

Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 31
Early research (Phase 1)Study completedNCT00720148
What this trial is testing

A Phase I Trial of Bortezomib and Sunitinib

Who this might be right for
Solid Tumors
Emory University 30
Testing effectiveness (Phase 2)Ended earlyNCT01163786
What this trial is testing

A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD

Who this might be right for
Bronchiolitis Obliterans
Northwestern University 17
Testing effectiveness (Phase 2)Ended earlyNCT00103376
What this trial is testing

Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

Who this might be right for
Prostate Cancer
Medical University of South Carolina 23
Testing effectiveness (Phase 2)Study completedNCT02206425
What this trial is testing

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Oncotherapeutics 45
Testing effectiveness (Phase 2)Study completedNCT01281917
What this trial is testing

Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkins Lymphoma
University of Wisconsin, Madison 40
Testing effectiveness (Phase 2)Study completedNCT00063713
What this trial is testing

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Who this might be right for
Mantle Cell Lymphoma
Millennium Pharmaceuticals, Inc. 152
Testing effectiveness (Phase 2)Ended earlyNCT00765102
What this trial is testing

Trial of Romidepsin and Bortezomib for Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 32
Large-scale testing (Phase 3)Study completedNCT03234972
What this trial is testing

Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 213
Testing effectiveness (Phase 2)Ended earlyNCT01465386
What this trial is testing

Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

Who this might be right for
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Myeloblastic Leukemia Without Maturation (M1)+9 more
Fred Hutchinson Cancer Center 6
Post-approval studies (Phase 4)Study completedNCT02844322
What this trial is testing

The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia

Who this might be right for
Waldenström Macroglobulinemia
Institute of Hematology & Blood Diseases Hospital, China 35
Testing effectiveness (Phase 2)WithdrawnNCT01460602
What this trial is testing

Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma

Who this might be right for
Follicular LymphomaMarginal Zone LymphomaMantle Cell Lymphoma
Louisiana State University Health Sciences Center Shreveport
Early research (Phase 1)Study completedNCT01359657
What this trial is testing

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 46
Testing effectiveness (Phase 2)Study completedNCT01720875
What this trial is testing

Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)

Who this might be right for
Multiple Myeloma
University of Leeds 16
Early research (Phase 1)Study completedNCT01174888
What this trial is testing

Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia FollowingMyelodysplastic Syndrome+8 more
Alison Walker 34
Testing effectiveness (Phase 2)Study completedNCT00116961
What this trial is testing

Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Michigan Rogel Cancer Center 40
Testing effectiveness (Phase 2)UnknownNCT02027220
What this trial is testing

Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma

Who this might be right for
MyelomaBortezomibCyclophosphamide+2 more
Second Affiliated Hospital of Soochow University 60
Not applicableUnknownNCT05218603
What this trial is testing

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

Who this might be right for
Multiple MyelomaNon-eligible for Autologous Stem Cell Transplantation (ASCT)
PETHEMA Foundation 100
Load More Results